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Abstract
Background: The Lives Saved Tool (LiST) model was developed to estimate the impact of the scale-up of child
survival interventions on child mortality. New advances in antimalarials have improved their efficacy of treating
uncomplicated and severe malaria. Artemisinin-based combination therapies (ACTs) for uncomplicated Plasmodium
falciparum malaria and parenteral or rectal artemisinin or quinine for severe malaria syndromes have been shown
to be very effective for the treatment of malaria in children. These interventions are now being considered for
inclusion in the LiST model. However, for obvious ethical reasons, their protective efficacy (PE) compared to
placebo is unknown and their impact on reducing malaria-attributable mortality has not been quantified.
Methods: We performed systematic literature reviews of published studies in P. falciparum endemic settings to
determine the protective efficacy (PE) of ACT treatment against malaria deaths among children with
uncomplicated malaria, as well as the PE of effective case management including parenteral quinine against
malaria deaths among all hospitalized children. As no randomized placebo-controlled trials of malaria treatment
have been conducted, we used multiple data sources to ascertain estimates of PE, including a previously
performed Delphi estimate for treatment of uncomplicated malaria.
Results: Based on multiple data sources, we estimate the PE of ACT treatment of uncomplicated P. falciparum
malaria on reducing malaria mortality in children 1–23 months to be 99% (range: 94-100%), and in children 24-59
months to be 97% (range: 86-99%). We estimate the PE of treatment of severe P. falciparum malaria with effective
case management including intravenous quinine on reducing malaria mortality in children 1-59 months to be 82%
(range: 63-94%) compared to no treatment.
Conclusions: This systematic review quantifies the PE of ACT used for treating uncomplicated malaria and effective
case management including parenteral quinine for treating severe P. falciparum malaria for preventing malaria
mortality in children <5. These data will be used in the Lives Saved Tool (LiST) model for estimating the impact of
scaling-up these interventions against malaria. However, in order to estimate the reduction in child mortality due
to scale-up of these interventions, it is imperative to develop standardized indicators to measure population
coverage of these interventions.
Background
Malaria remains a serious global public health problem,
with nearly one-third of the world population exposed
to stable Plasmodium falciparum transmission, the spe-
cies responsible for most malaria deaths [1]. WHO has
estimated that 243 million malaria cases and 863,000
malaria deaths occurred globally in 2009, with over 90%
occurring in sub-Saharan Africa [2].
Artemisinin combination therapies (ACT) are highly
effective for preventing an uncomplicated P. falciparum
malaria fever from progressing to severe disease, which
can result in death [3,4]. Nearly all endemic countries
have now adopted ACT as the first-line treatment for P.
falciparum malaria [5]. Among children with severe
malaria, effective case management with parenteral or
rectal artemisinin or quinine is also recognized to be
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any medium, provided the original work is properly cited.highly effective at preventing death [6-8]. More recently,
a large scale trial of intravenous artemisinin has been
shown to reduce mortality compared to quinine in Afri-
can children with severe malaria [9]. However, the
impact of prompt and effective treatment of uncompli-
cated malaria and case management of severe malaria
on reducing child malaria deaths has not been quanti-
fied with placebo-randomiz e dc o n t r o l l e dt r i a l sf o r
obvious ethical reasons.
In the absence of sufficient systems to monitor real-
time trends in cause-specific child mortality in many
developing countries, mathematical models are increas-
ingly being used to estimate the impact of the scale-up of
child survival interventions on child mortality. The Lives
Saved Tool (LiST) is one such model developed by WHO
and UNICEF’s Child Health Epidemiology Reference
Group (CHERG) and based on the earlier work on effec-
tiveness of interventions [10]. The model estimates child
deaths prevented (within specific cause of death cate-
gories) due to intervention scale-up within a specified
country as a function of three primary parameters: 1) the
number of child deaths by cause projected to occur in
each year (including population growth parameters over
time); 2) the protective efficacy (PE) on cause-specific
mortality (PE = 1 - relative risk (RR) * 100) for each inter-
vention being scaled-up; and 3) increases in population
coverage of each intervention [11].
We performed systematic literature reviews to identify
studies that could be used to estimate the effect of
prompt effective treatment of uncomplicated malaria
and effective case management of severe malaria for
preventing post-neonatal child malaria deaths, defined
here as mortality directly following a clinical episode of
malaria (within a 28 day follow up period for uncompli-
cated and during hospitalization for severe) in children
1-59 months (assuming no malaria deaths occur or
could be accurately attributed during the neonatal per-
iod). We chose to focus on sub-Saharan Africa, given
the vast majority of childhood deaths due to malaria
occur there and as results obtained in this zone of pri-
marily stable transmission may not apply to zones of
unstable transmission. Results for the systematic reviews
will be considered for default values for PE for the inter-
ventions to be included in the LiST model.
Methods
These intervention effectiveness reviews were shaped in
large part by the needs of the LiST model, as presented
elsewhere [11]. In the LiST model, increases in coverage
of an intervention result in a reduction of one or more
cause-specific deaths or in reduction of a risk factor for
death. Therefore the reviews and the grade process were
designed to develop estimates of the effect of an inter-
vention in reducing a death due to specific cause. A set
of rules were also established and followed for generat-
ing estimated intervention effects for use in LiST, as
presented elsewhere [11].
To quantify the PE of case management of uncompli-
cated and severe malaria for preventing malaria deaths
in children, we conducted a systematic literature review
to identify randomized controlled trials using PubMed.
Studies were limited to those implemented in areas of
endemic P. falciparum malaria transmission. Where suf-
ficient data from individual or community-randomized
controlled trials could not be identified, we considered
all available evidence, including observational and Del-
phi studies, in quantifying the PE of interventions
reviewed here. Where possible, study quality was
assessed according to the GRADE technique [12],
adapted by the Child Health Epidemiology Reference
Group as outlined elsewhere [11]. We assessed the qual-
ity of the data sources contributing to each CFR esti-
mate as high, moderate, or low (Table 1).
A malaria death is defined as one death per parasitolo-
gically diagnosed clinical episode. It is recognized that
non-lethal episodes of malaria frequently result in
increased vulnerability to other infectious diseases and
subsequent death due to another cause. Some have sug-
gested that the likelihood of dying in the 8 weeks fol-
lowing discharge from a malaria diagnosis is equal to
the likelihood of dying in the hospital [13]. However,
lack of sufficient data precluded the inclusion of such
deaths due indirectly to a P. falciparum infection.
Prompt treatment of uncomplicated malaria with
effective antimalarials
We sought to measure the PE of prompt ACT treat-
ment of uncomplicated malaria for preventing child
malaria mortality, as compared with no treatment, in
Table 1 Quality of sources of data for estimates
Data source Number of studies Data source quality
Uncomplicated malaria - untreated Delphi method 1 low
Uncomplicated malaria - treated Deaths reported in clinical trials of ACTs for uncomplicated
malaria
49 high
All hospitalized malaria - untreated Mortality when treated with CQ in setting of high CQ resistance –
hospital observational studies
2 low
All hospitalized malaria - treated Mortality in hospitals offering high standards of care - hospital
observational studies
4 moderate
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malaria was defined as illness, febrile or otherwise, for
which treatment was sought, with confirmation of a
P. falciparum infection, either by microscopy or rapid
diagnostic test. Given the absence of placebo-controlled
trials of treatment of uncomplicated malaria, we adopted
the following approach to estimate a relative risk for
ACT versus no treatment of uncomplicated malaria for
preventing malaria mortality, which requires the rate of
malaria death (observed) in those treated with ACT and
the rate of death in those untreated (natural history). A
comprehensive and thorough review of comparative
effectiveness studies of ACTs against other antimalarials
for uncomplicated malaria was published in 2009 [3].
We retrieved the articles included in this review and
abstracted mortality from each trial to determine case
fatality ratios (CFR) despite prompt and effective treat-
ment of uncomplicated malaria. The mean CFR across
all trials used in this analysis was weighted by the sam-
ple size reported in each study. While literature searches
to determine natural history of untreated uncomplicated
falciparum malaria in children were fruitless, Sudre and
Breman conducted a study using the Delphi method to
garner expert opinion on the proportion of otherwise
healthy children who would die from uncomplicated
malaria if left untreated, within an area of stable P. falci-
parum transmission in Africa [14]. They found that
experts estimated mortality in untreated children <2
years old with uncomplicated P. falciparum malaria to
be 5%, and in untreated 2-5 year olds to be 2%. We
used these estimates as proxies for mortality of
untreated uncomplicated malaria (natural history). We
estimated uncertainty using a sensitivity analysis. For
the lower bound, the CFR among treated children was
assumed double the observed estimate and the CFR
among untreated children was assumed to be half the
Delphi estimate. For the upper bound, the CFR among
treated children was assumed half the observed estimate
and the CFR among untreated children was assumed to
be double the Delphi estimate.
Effective case management of children hospitalized with
malaria
We sought to estimate the PE of effective case manage-
ment with intravenous quinine of children hospitalized
with malaria for preventing child malaria mortality, as
compared with no treatment, in sub-Saharan Africa.
While severe disease treatment trials often focus on a
restricted spectrum of severity, (e.g. only including cere-
bral malaria), in practice, children hospitalized with
m a l a r i ad e m o n s t r a t eav a r i e ty of syndromes, including
prostration, intractible vomiting, respiratory distress,
severe malarial anemia, hypoglycaemia (often iatrogenic),
multisystem organ failure, and cerebral malaria. A
stringent definition of severe malaria is often applied for
research purposes, but for programmatic uses, such as
the LiST model, data regarding hospitalization and out-
comes are more likely to be available for all hospitalized
children. Thus we attempted to calculate protective effi-
cacy of case management with intravenous quinine for
all children hospitalized with malaria, for greatest pro-
grammatic utility.
We used observational trials and retrospective data
reviews to examine treated and untreated mortality for
all children hospitalized with malaria. We searched
PubMed using the terms “severe malaria” and “mortal-
ity” to search for studies on mortality due to malaria in
hospitalized African children to attempt to ascertain the
CFR of malaria in this setting. Any hospital-based study
conducted in a zone of stable transmission in sub-
Saharan Africa that reported the proportion of children
admitted with a diagnosis of malaria that had a fatal
outcome was included.
From each report, we abstracted definitions of sever-
ity, quality of care, antimalarial used, age range, country,
urban or rural environment, number of children
included, and number of deaths. For studies in which
one or more categories of the above were documented,
we abstracted each separately. Studies that reported the
outcome of all hospitalized children and offered care
rated moderate to good were included in the estimate of
CFR for hospitalized children with effective case man-
agement with intravenous quinine.
There are no randomized-placebo controlled trials to
determine mortality reduction due to effective treatment
of hospitalized children. As a proxy for the natural his-
tory of mortality of children eligible for hospitalization
with malaria, we used mortality of children hospitalized
with malaria in the setting of chloroquine failure,
reported in two retrospective reviews retrieved through
the above search. We recognize this will likely result in
an underestimation of the natural history of mortality in
children who went untreated for malaria requiring hos-
pitalization, which would result in an underestimation
of the protective efficacy of effective case management
of severe malaria.
PE was calculated using the weighted mean CFR of
children treated with effective case management with
intravenous quinine, and the average of the two observa-
tional studies in the setting of chloroquine failure (we did
not weight this due to the unbalanced sample sizes) for
the natural history. For calculation of uncertainty sur-
rounding protective efficacy, we conducted a sensitivity
analysis, using the 95% confidence limits of the weighted
mean CFR as upper and lower bounds in children with
effective case management, and the range of CFR in the
two retrospective studies as the upper and lower bounds
of mortality in the setting of chloroquine failure.
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Treatment of uncomplicated malaria with effective
antimalarials
Among the 49 double-blind randomized placebo con-
trolled equivalency trials identified from our review
[15-63], the weighted mean CFR among children with
uncomplicated P. falciparum malaria treated promptly
with an ACT was 0.068% (11 / 16,086) (95% CI .024-
.112); an additional 67 cases were reported as early
treatment failures that received rescue therapy and
went on to recovery. These trials largely did not report
the timing or other details for each death. This was
used as the mortality in children receiving the inter-
vention of prompt treatment with ACT. The estimates
of 5% mortality and 2% mortality for untreated chil-
dren <2 and 2-5 years old, respectively, were used as
the proxy for the natural history of mortality in
untreated children with uncomplicated P. falciparum
malaria. Based on these findings, the PE of prompt
treatment of uncomplicated P. falciparum malaria with
ACT was estimated to be 99% (range 94 – 100%) for
children <2 years old and 97% (range 86 – 99%) for
children 2-5 years old (Table 2).
Effective case management of hospitalized children with
malaria
Seventeen studies were identified that reported hospital-
based mortality data in children in zones of stable trans-
mission in sub-Saharan Africa [64-80]. Wide variations
were seen in quality of care offered, stringency of defini-
tion of severe malaria, and CFR (Additional File 1).
When studies that offered moderate to high quality care
and documented outcomes of all hospitalized children
with a primary diagnosis of malaria were included, the
weighted mean CFR was 3.4% (95% CI 1.6-5.2). When
the definition was restricted to children with severe dis-
ease, the weighted mean CFR was 13.6% (95% CI 8.4-
18.8). In the years immediately following the spread of
chloroquine resistance (late 1980s), children who contin-
ued to be treated with chloroquine had approximately a
three-fold higher CFR than children treated with an
effective antimalarial [81]. Two studies were identified
that reported hospital-based mortality data examining
the impact of chloroquine resistance on mortality. CFRs
in the setting of chloroquine failure were 13.1% (39/296)
and 21.1% (500/2374) in two studies in hospitals that
otherwise offered a high standard of care [67,82]. The
resultant protective efficacy was 82%, with a sensitivity
analysis range of 63-94% (Table 3).
Discussion
We performed systematic reviews to quantify estimates
of PE for the following interventions for preventing
m o r t a l i t yd u ed i r e c t l yt om a l a r i ai nc h i l d r e ni ns u b -
Saharan Africa: prompt effective case management with
ACTs for uncomplicated malaria, and effective case
management with intravenous quinine of children hos-
pitalized with malaria. The lack of controlled trials and
the need to use numerous lower quality data sources
make this exercise challenging.
Given the lack of placebo-controlled trials of treat-
ment for malaria due to ethical reasons, we were unable
to directly determine PE for prompt effective treatment
of uncomplicated malaria for preventing malaria child
mortality, as compared to no treatment. A meta-analysis
was used to quantify the CFR for children with uncom-
plicated malaria that received prompt effective
treatment. Results showed that death following uncom-
plicated malaria treated promptly with an effective anti-
malarial is very rare (0.068%, 95% CI 0.024 – 0.112).
Because of a paucity of available data, we based the esti-
mate of the natural mortality history of uncomplicated
P. falciparum malaria on a previously published Delphi
method, which found that experts estimated the risk of
death among untreated children with uncomplicated P.
falciparum malaria to be 5% for <2 year olds and 2% for
2-5 year olds. Combining these estimates, we estimated
a very high PE of prompt ACT treatment of uncompli-
cated malaria compared to no treatment [99%
(94-100%) for children younger than 2 years old, and
97% (86-99%) for children 2-5 years old].
For programmatic utility, we estimated a PE of effec-
tive case management of all children hospitalized with
malaria. The CFR of 3.4% (95% CI 1.6-5.2) for all
Table 2 Estimates of protective efficacy of prompt ACT treatment for uncomplicated P. falciparum malaria
Child
age
CFR among children receiving no
treatment (per 10,000) [14]
Estimated CFR among children receiving prompt







<2 years 500 6.8 98.6% 94.4% 99.7%
2-5 years 200 6.8 96.6% 86.0% 99.3%
CFR: case fatality ratio.
Protective efficacy = (1-Relative risk) * 100, where Relative risk = CFR receiving ACT / CFR no treatment.
Lower bound based on sensitivity analysis where CFR among treated children assumed double (14 per 10,000) and CFR among untreated children assumed to
be half (250 and 100 per 10,000 for children <2 and 2-5 years old, respectively).
Upper bound based on sensitivity analysis where CFR among treated children assumed to be half (3 per 10,000) and CFR among untreated children assumed to
be double (1,000 and 400 per 10,000 for children <2 and 2-5 years old, respectively).
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similar to that found by other authors [71,81,82], and
the CFR of 13.6% for strictly defined malaria is slightly
higher than the AQUAMAT trial [9], not surprising for
observational studies compared to clinical trial condi-
tions. As a proxy for mortality of untreated hospitalized
malaria (natural history), we used mortality data from
observational studies in the setting of chloroquine fail-
ure, during the era when chloroquine resistance was
being established and chloroquine was still in wide-
spread use. This resulted in the estimated CFR of
untreated hospitalized malaria ranging from 13-21%.
The higher bound (21%) is problematic, as the majority
of the children in this sample who died had received
chloroquine, and died despite respite receiving intrave-
nous quinine after being admitted in critical condition,
thus it may be a major underestimation. A qualitative
study in Mali found that mortality for severe malaria (by
maternal definition during interview) was 17.0% regard-
less of treatment-seeking [83], which falls in the middle
of this range and lends some credence to its accuracy.
Thus we believe that a PE of 82% for protective efficacy
of effective case management with intravenous quinine
is reasonable. Given that these studies all used intrave-
nous quinine, the PE of intravenous artesunate for pre-
venting mortality would be expected to be even higher.
There are numerous limitations to using the LiST
model to predict the number of child deaths that
could be prevented by scaling-up case management of
uncomplicated and severe malaria. First, no placebo-
controlled data exists and the historical literature is of
insufficient quality to establish a CFR for children who
go untreated for uncomplicated and severe P. falci-
parum malaria (natural history). For uncomplicated P.
falciparum malaria, we relied on expert opinion from a
Delphi survey to obtain an estimate of the probability
of a child dying following uncomplicated P. falciparum
malaria when left untreated, within the context of
stable transmission. Such an estimate from a Delphi
study is clearly subject to bias, although the direction
and magnitude are unknown. For estimating the prob-
ability of a child dying from severe P. falciparum
malaria when left untreated, we relied on a proxy esti-
mated as the probability of a child dying from severe
malaria after treatment with chloroquine, in the con-
text of high chloroquine resistance, which ranged from
13.1-21.1%. While this was a helpful proxy, it likely
underestimates the true untreated CFR and therefore
underestimates the true PE of case management of
children hospitalized with P. falciparum malaria. Sec-
ond, while the majority of children with uncomplicated
malaria are still not treated with an ACT, and many
hospitalized children receive inadequate care, often
with sub-optimal medication as well as ancillary treat-
m e n t ,m a n yd or e c e i v es o m ef o r mo ft r e a t m e n t .T h u s
hospitalized children who had received chloroquine
likely had somewhat better outcomes than children
who received no treatment. Third, our approach takes
into account only a given episode of malaria, and does
not take into account longitudinal impact of adequate
or inadequate treatment, or the post-prophylactic
effect of some antimalarials. If more reliable estimates
of untreated mortality of uncomplicated and severe
disease become available, it will be important to
update the estimates. Finally, while it would be optimal
to generate these estimates for children with strin-
gently defined severe malaria, as CFR for severe
malaria after treatment with intravenous artesunate
has been well documented, no proxy for untreated
mortality in severe disease currently exists. If these
data become available, the protective efficacy of case
management with intravenous artesunate in this subset
of children should be estimated.
Case management coverage indicators in most
sub-Saharan African countries lag far behind coverage
indicators for malaria prevention, in part because the
delivery of effective case management of both uncompli-
cated and severe disease is quite complex and involves
not only procurement of the drugs, but supply chain
management, health worker training and supervision,
revision of payment schemes to remove financial bar-
riers, extending this care to more peripheral levels of
the health care system, and working to encourage use of
these services by the population.
Table 3 Estimates of protective efficacy of case management with intravenous quinine for children hospitalized with
P. falciparum malaria
CFR range among children not
receiving effective treatment
Estimated CFR range among
children receiving intravenous
quinine
PE range using CFR of 3.4% for







13.1%-21.1% 3.4% (95% CI 1.6-5.2) 76-87% 82% 63% 94%
CFR: case fatality ratio.
Protective efficacy = (1-Relative risk) * 100, where Relative risk = CFR receiving intravenous quinine / CFR not receiving effective antimalarial.
Lower bound based on sensitivity analysis where CFR among treated children is the upper bound for 95% confidence interval and CFR among untreated children
is the lower of the two values for untreated children.
Upper bound based on sensitivity analysis where CFR among treated children is the lower bound for 95% confidence interval and CFR among untreated children
is the higher of the two values for untreated children.
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prompt effective treatment is the proportion of children
<5 years old with fever in the past two weeks who
received an ACT within 24 hours from the onset of
fever [84]. While an attempt has been made to standar-
dize this indicator to be measured by most nationally-
representative household surveys (e.g. Demographic and
Health Survey, UNICEF’s Multiple Indicator Cluster
Survey and Malaria Indicator Surveys), it is problematic
for measuring trends in coverage over time for several
reasons. First, as scale-up of prevention interventions
such as ITNs increases, the proportion of fevers due to
malaria is likely to decrease. Second, most countries
have now adopted the policy of laboratory diagnosis [5],
with either microscopy or rapid diagnostic tests, for all
suspected malaria cases seeking treatment through the
health system. For this reason when assessing trends in
coverage for prompt effective treatment of malaria
fevers, the proportion receiving treatment has actually
gone down in most countries since 2005 as countries
have switched from clinical diagnosis to laboratory diag-
nosis. Finally, most countries switched their first-line
antimalarial from a monotherapy to an often less avail-
able ACT within the last 5-8 years [5], decreasing treat-
ment with a recommended first line antimalarial in
some countries over the past decade.
There is currently no established indicator for mea-
suring the proportion of children hospitalized with P.
falciparum malaria that receive effective case manage-
ment. Establishing such an indicator will be difficult.
Mortality of hospitalized patients depends not only on
the quality of care received once hospitalized, but the
delay in reaching such care, which depends on multi-
ple factors including the distance to referral level care,
availability of transportation, and cost of treatment,
each of which may increase the delay and decrease the
likelihood that the child will reach referral level care.
However, programs are much more likely to be able to
collect and report data on the management and out-
comes of all children hospitalized with malaria than of
a subset of children with stringently defined severe
malaria.
Conclusions
This systematic review attempted to quantify the PE of
ACT used for treating uncomplicated malaria and effec-
tive case management with intravenous quinine for
treating severe P. falciparum malaria for preventing
malaria mortality in children <5. While there have been
no placebo-controlled randomized trials of ACTs for
uncomplicated disease and parenteral quinine or artemi-
sinins for severe disease, our analysis shows these strate-
g i e st ob eah i g h l ye f f e c t i v et r e a t m e n ti np r e v e n t i n g
malaria mortality in children, preventing nearly all
(>95%) deaths that would result from uncomplicated P.
falciparum malaria if left untreated, and over three-
quarters (82%) of deaths in children with hospitalized P.
falciparum malaria, compared to hospitalization without
effective malaria treatment. Given standardized and
valid coverage indicators can be developed, these PE
estimates will allow the use of the LiST model for esti-
mating the likely impact of past treatment scale-up, as
well as for predicting future impact of treatment scale-
up by national malaria control programs.
In this manuscript, we have provided our best effort at
identifying methods to characterise the PE estimate for
prompt effective malaria treatment for uncomplicated
and severe malaria. We are now faced with the dilemma
that there is currently no standardized indicator for
both the true frequency of disease or access to these
interventions in the population. While we welcome
debate on the PE estimates we have generated, as well
as future refinements, it is critical to develop standar-
dized coverage indicators to measure progress, now and
in the future. At this point, the coverage of good case
management is low in most sub-Saharan African coun-
tries. In order to track progress as good case manage-
ment coverage improves, we need standardized
population-based estimates of the following: 1) propor-
tion of children <5 with uncomplicated malaria receiv-
ing an ACT and receiving no treatment; and 2) the
proportion of children <5 eligible for hospitalization
with malaria receiving effective case management with
intravenous quinine or artemisinin and receiving no
treatment. It is imperative that the malaria community
act now to establish these measures, test means of asses-
sing them, and insert them into surveys and other popu-
lation-based measurement tools that will allow tracking
them over time.
Additional material
Additional file 1: Web appendix reporting the characteristics of
observational studies of case fatality rates in children hospitalized
for malaria, broken into subgroups where multiple levels of
severity or quality of care were reported
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